Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06204159 · ClinicalTrials.gov registry record · NA
Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
A NA study of Hepatocellular Carcinoma and Neuroendocrine Tumors, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT06204159: Active NA study of Hepatocellular Carcinoma and Neuroendocrine Tumors, sponsored by Abramson Cancer Center at Penn Medicine.
NCT06204159 is a NA study of Hepatocellular Carcinoma and Neuroendocrine Tumors that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 12 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06204159, a NA study of Hepatocellular Carcinoma and Neuroendocrine Tumors, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to compare CT scan of the coverage of tumors treated with TACE using End Hole catheters to those treated with the TriNav catheter that alters tissue pressure. Both catheters are FDA approved for delivery of TACE. • Is there a difference in CT appearance with delivery in the type of catheter used during the TACE procedure? Participants will be asked to undergo a TACE procedure, a CT scan and review of their medical record to compare End Hole and TriNav catheters during TACE procedures.
Primary Outcome
To estimate the relative volume and density of lipiodol deposition in hypervascular liver tumors
Conditions Studied
Interventions
- DEVICE TACE Catheters
Study Locations (2)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
- University of Pennsylvania, Department of Radiology, Interventional Radiology Division - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What the registry record for NCT06204159 still lists
NCT06204159 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which TACE Catheters is the first listed.
NCT06204159 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06204159 about?
NCT06204159 is a clinical study titled "Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery". The goal of this clinical trial is to compare CT scan of the coverage of tumors treated with TACE using End Hole catheters to those treated with the TriNav catheter that alters tissue pressure. Both catheters are FDA approved for delivery of TACE. • Is there a difference in CT appearance with deliv...
What is the current status of trial NCT06204159?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2024-02-01. Estimated completion is 2026-06-30.
What conditions does trial NCT06204159 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Neuroendocrine Tumors.
What interventions are being tested in trial NCT06204159?
The interventions under investigation include: TACE Catheters (DEVICE).
Who is sponsoring clinical trial NCT06204159?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06204159 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06204159's enrollment target sits among peer trials
12 137th of 145 higher than 7 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RECRUITING · NA
-
Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
RECRUITING · NA
-
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI